EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Treatment Pathways in Patients With Crohn’s Disease and Ulcerative Colitis: Understanding the Road to Advanced Therapy

Corey A Siegel iD, Dolly Sharma, Jenny Griffith, Quynhchau Doan, Si Xuan, Lisa Malter

Crohn's & Colitis 360 · 01.07.2024 · 6 (3)

DOI: 10.1093/crocol/otae040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Crohn's & Colitis 360, online erschienen am 20.08.2024. Verfasst von Corey A Siegel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Inflammatory Bowel Disease Center, Section of Gastroenterology and Hepatology, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with Crohn’s disease (CD) or ulcerative colitis (UC) often cycle through conventional therapies (CT) with different mechanisms of action (MOA) before initiating advanced therapy (AT). We describe treatment patterns among patients with CD/UC.

Methods

Using Merative MarketScan Research databases, adult patients with CD/UC were identified from medical/pharmacy claims (2017–2021). Patients had ≥1 hospitalization or ≥2 outpatient visits (≥30 days apart within 1 year) for CD/UC. Two cohorts were established; cohort 1: Newly diagnosed patients (index date is the date of first diagnosis) and cohort 2: Patients initiating AT (index date is the date of first AT). First-line treatment patterns (cohort 1) and CT pathways before AT initiation (cohort 2) by the number of episodes (ie, adding a new therapy, switching to another therapy, or restarting the same therapy after ≥60 days) and MOA are reported.

Results

Among newly diagnosed patients in cohort 1 (CD: n = 1739; UC: n = 2740), 14.4% (CD) and 5.9% (UC) of patients had any AT use during the follow-up period (mean: 2.3 years; ≥ 77% initiated corticosteroids). Among patients in cohort 2 (CD: n = 2594; UC: n = 2431), the mean number of CT episodes before AT initiation was 4.0 ± 4.3 (CD) and 5.9 ± 5.0 (UC). Among those with ≥1 corticosteroid episode (CD: 82.2%; UC: 91.5%), the mean number of episodes was 4.6 ± 4.3 (CD) and 6.3 ± 5.0 (UC). Overall, 13.3% (CD) and 23.7% (UC) of patients cycled through 3 MOAs before AT initiation.

Conclusions

Despite treatment recommendations, few newly diagnosed CD/UC patients initiated AT as their first treatment. Moreover, patients cycled through multiple CTs before initiating AT.

Schlagwörter

Stichwörter der Autor:innen

Crohn’s diseasetreatment patternsulcerative colitis

Autor:innen und Institutionen

  • Inflammatory Bowel Disease Center, Section of Gastroenterology and Hepatology, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA.
  • Department of Health Economics and Outcomes Research, AbbVie, Inc, North Chicago, IL, USA.
  • Division of Gastroenterology, Department of Medicine, New York University Langone Medical Center, New York, NY, USA.

ORCID-Profile: Corey A Siegel

Förderung

  • AbbVie

Zitieren

APA

Siegel, C. A., Sharma, D., Griffith, J., Doan, Q., Xuan, S., & Malter, L. (2024). Treatment Pathways in Patients With Crohn’s Disease and Ulcerative Colitis: Understanding the Road to Advanced Therapy. Crohn's & Colitis 360, 6(3). https://doi.org/10.1093/crocol/otae040

Vancouver

Siegel CA, Sharma D, Griffith J, Doan Q, Xuan S, Malter L. Treatment Pathways in Patients With Crohn’s Disease and Ulcerative Colitis: Understanding the Road to Advanced Therapy. Crohn's & Colitis 360. 2024;6(3). doi:10.1093/crocol/otae040

BibTeX
@article{Siegel2024,
  author = {Siegel, Corey A and Sharma, Dolly and Griffith, Jenny and Doan, Quynhchau and Xuan, Si and Malter, Lisa},
  title = {Treatment Pathways in Patients With Crohn’s Disease and Ulcerative Colitis: Understanding the Road to Advanced Therapy},
  journal = {Crohn's & Colitis 360},
  year = {2024},
  volume = {6},
  number = {3},
  doi = {10.1093/crocol/otae040}
}
Kostenlos starten →